Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHSCT for severe treatment-resistant neuroimmunological disease
ACTRN12622000530729Phase 2Recruiting
- Sponsor
- St Vincent's Hospital
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, rituximab, antithymocyte globulin rabbit, autologous haematopoietic stem cells and granulocyte colony-stimulating factor in neuromyelitis optica (NMO), stiff person syndrome (SPS), myasthenia gravis (MG) and 1 more, sponsored by St Vincent's Hospital. Primary endpoints: Safety: length of stay after AHSCT, Safety: time to engraftment and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
cyclophosphamiderituximabantithymocyte globulin rabbitautologous haematopoietic stem cellsgranulocyte colony-stimulating factor
03
Conditions
neuromyelitis optica (NMO)stiff person syndrome (SPS)myasthenia gravis (MG)cerebral arteritis (CNSV)
Beyond the preview
Go deeper on ACTRN12622000530729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000530729.